Sleven, Sarissa did not take over to run the business. They came in to structure a high level exit. This is not a passive fund sitting on losses and hoping to grow an asset. They took control of the board, cut burn, and promoted Berg internally because they knew he would stay aligned with the agenda already in motion. Saying they played around in Europe completely misreads the sequence. The EU patent extension pushing protection to 2039 was granted in April of last year. That was step one. After Q2 earnings, Amarin went quiet on Germany and France, not out of indecision but because coordination with Recordati had already begun. The same day the Recordati deal was announced, Amarin quietly launched a microsite confirming that revised strategies for both markets had been identified with Recordati taking the lead. Silence was never a stall. It was part of the handoff. By June of this year, full EU commercialization was handed over to Recordati, a partner with deep ties to Novartis. That was not retreat. It was buyer aligned simplification. This board was never going to build out Europe on their own. Their role was to secure reimbursement, protect IP, and step aside. The buyback was approved but never executed. They said they were monitoring market conditions but once buyer discussions progressed, it was off the table. Insider purchases also stopped long before that which likely marked the beginning of MNPI restrictions. Under the UK Takeover Code, share repurchases and insider buying are prohibited during a live deal process. The twenty for one reverse split was not failure. It was a float reset to increase per share leverage heading into a premium transaction. Barclays is still advising for a reason. The silence in the United States is not confusion. It is legal containment. If a buyer like Novartis is finalizing mechanics, Amarin’s role is to stay quiet, let the catalysts hit, and deliver a clean de risked patent secured platform. LR-EtEPA is the centerpiece. Everything else has been setup. Sarissa did not take over to operate the company. They came here to sell it. And they have already built the structure to do it. You said these guys do not know how to run a pharmaceutical company? Good, because they are not trying to run one. They are here to sell it just like they have done before. The average adjusted exit value across their last four sales is 9.15 billion. That is what they do, and this one is already halfway out the door. Given how far off your guesses about Amarin have been, you should probably be the last person making assumptions about anyone else’s drug use. Maybe it is time to stop drinking and read the filings.
Bullish
Market Data 
Markets 
